Pfizer’s Tanezumab For Pain Turns Heads At Rheumatology Meeting
This article was originally published in The Pink Sheet Daily
Executive Summary
Firm looking at 2011-2012 filing for drug candidate, now in Phase III.
You may also be interested in...
Pfizer/Lilly Had Big Ambitions For Tanezumab; Are They Finally Dashed?
Given serious safety questions with tanezumab, the US filing seemed like throwing a Hail Mary; two FDA advisory panels overwhelmingly rejected the proposed risk management plan.
Future Appears Grim For Pfizer's Tanezumab With Ostearthritis Trial Stopped
Because tanezumab is the anti-NGF farthest along in development, adverse event reports could spell trouble for the entire planned class of analgesics.
Future Appears Grim For Pfizer's Tanezumab With Ostearthritis Trial Stopped
Because tanezumab is the anti-NGF farthest along in development, adverse event reports could spell trouble for the entire planned class of analgesics.